MedPath

Carvedilol

Generic Name
Carvedilol
Brand Names
Coreg
Drug Type
Small Molecule
Chemical Formula
C24H26N2O4
CAS Number
72956-09-3
Unique Ingredient Identifier
0K47UL67F2
Background

Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker. It is currently used to treat heart failure, left ventricular dysfunction, and hypertension. The dual action of carvedilol is advantageous in combination therapies as moderate doses of 2 drugs have a decreased incidence of adverse effects compared to high dose monotherapy in the treatment of moderate hypertension.

Carvedilol was granted FDA approval on 14 September 1995.

Indication

Carvedilol is indicated to treat mild to severe heart failure, left ventricular dysfunction after myocardial infarction with ventricular ejection fraction ≤40%, or hypertension.

Associated Conditions
Atrial Fibrillation, Chronic Stable Angina Pectoris, Hypertension, LVEF ≤40% Left ventricular dysfunction, NYHA Class I or II heart failure, Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV)
Associated Therapies
-
Clinical Trials
Related News

Conditioned Pharmacotherapeutic Effects in Hypertension

Phase 4
Completed
Conditions
Hypertension
Interventions
Drug: carvedilol
First Posted Date
2014-02-06
Last Posted Date
2019-07-09
Lead Sponsor
University of Rochester
Target Recruit Count
44
Registration Number
NCT02056626
Locations
🇺🇸

University of Rochester, Rochester, New York, United States

Study to Compare the Pharmacokinetic Characteristics and Safety of Dilatrend SR Capsule 32mg and Dilatrend Tablet 25mg

Phase 1
Conditions
Congestive Heart Failure
Essential Hypertension
Chronic Stable Angina
Interventions
Drug: Dilatrend SR capsule 32mg
Drug: Dilatrend IR tablet 25mg
First Posted Date
2013-03-28
Last Posted Date
2013-04-01
Lead Sponsor
Chong Kun Dang Pharmaceutical
Target Recruit Count
48
Registration Number
NCT01819870
Locations
🇰🇷

Kyungpook National University Hospital Clinical Trial Center, Daegu, eok-dong 2(i)-ga Jung-gu, Korea, Republic of

Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart

Phase 4
Completed
Conditions
Idiopathic Dilated Cardiomyopathy
Interventions
Drug: Metoprolol succinate
Drug: Metoprolol succinate + doxazosin
Drug: Carvedilol
First Posted Date
2013-02-26
Last Posted Date
2023-11-29
Lead Sponsor
University of Colorado, Denver
Target Recruit Count
56
Registration Number
NCT01798992
Locations
🇺🇸

University of Colorado Hospital, Denver, Colorado, United States

🇺🇸

University of Utah Medical Center, Salt Lake City, Utah, United States

Efficacy and Safety of Carvedilol SR Versus Carvedilol IR in Patients With Essential Hypertension

First Posted Date
2012-12-27
Last Posted Date
2014-01-14
Lead Sponsor
Chong Kun Dang Pharmaceutical
Target Recruit Count
238
Registration Number
NCT01756430
Locations
🇰🇷

The Hanyang Universitiy Guri Hospital, Guri-si, Gyeonggi-do, Korea, Republic of

Carvedilol Effect in Preventing Chemotherapy - Induced Cardiotoxicity

Phase 3
Completed
Conditions
Breast Cancer
Heart Failure
Cardiotoxicity
Interventions
Drug: Placebo
Drug: Carvedilol
First Posted Date
2012-11-09
Last Posted Date
2018-02-05
Lead Sponsor
University of Sao Paulo
Target Recruit Count
200
Registration Number
NCT01724450
Locations
🇧🇷

Heart Institute University of Sao Paulo, Sao Paulo, Brazil

Beta Blockers for Treatment of Pulmonary Arterial Hypertension in Children

Phase 1
Withdrawn
Conditions
Pulmonary Arterial Hypertension
Interventions
Drug: Carvedilol
First Posted Date
2012-11-07
Last Posted Date
2015-12-31
Lead Sponsor
The Hospital for Sick Children
Registration Number
NCT01723371
Locations
🇨🇦

The Hospital for Sick Children, Toronto, Ontario, Canada

Non-selective Beta Blockers Versus EVL for Primary Prophylaxis of Esophageal Variceal Bleeding in Patients With Hepatocellular Carcinoma With Portal Vein Tumour Thrombosis.

Not Applicable
Withdrawn
Conditions
Hepatocellular Carcinoma With Portal Vein Thrombosis
Interventions
Procedure: Endoscopic Variceal Ligation
Drug: Carvedilol
First Posted Date
2012-08-07
Last Posted Date
2017-11-17
Lead Sponsor
Institute of Liver and Biliary Sciences, India
Registration Number
NCT01659346
Locations
🇮🇳

Institute of Liver and Biliary Sciences, New Delhi, Delhi, India

Beta Blocker Therapy in Moderate to Severe COPD

Phase 4
Completed
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Drug: Carvedilol
Drug: Bisoprolol
Drug: Beclometasone/formoterol
Drug: Tiotropium
Drug: Beclometasone
First Posted Date
2012-08-02
Last Posted Date
2019-04-23
Lead Sponsor
University of Dundee
Target Recruit Count
18
Registration Number
NCT01656005
Locations
🇬🇧

Asthma and Allergy Research Group, Ninewells Hospital and Medical School, University of Dundee, Dundee, United Kingdom

Carvedilol for Prevention of Paroxysmal Atrial Fibrillation

Not Applicable
Active, not recruiting
Conditions
Atrial Fibrillation
Interventions
Drug: Metoprolol
Drug: Carvedilol
First Posted Date
2012-05-31
Last Posted Date
2022-05-27
Lead Sponsor
University of Calgary
Target Recruit Count
300
Registration Number
NCT01608893
Locations
🇨🇦

University of Calgary, Calgary, Alberta, Canada

Use of Beta-blockers and Risk of New Onset Diabetes

Completed
Conditions
Hypertension
Interventions
Drug: carvedilol
Drug: cardio selective betablocker
First Posted Date
2012-04-30
Last Posted Date
2012-04-30
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
12336
Registration Number
NCT01587638
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy